The patentability of biotechnological inventions: The European Commission’s second 16c report Paul Van den Bulck Partner at Ulys Law Firm (Brussels) Lecturer.

Slides:



Advertisements
Similar presentations
Ethical aspects and Patents in Lifescience Peter R. Thomsen Manager Global IP Litigation, Corporate Intellectual Property, Novartis WIPO symposium on IP.
Advertisements

Workshop on wines for making a protected geographical indication Technical File Anabela Alves BELGRADE, SERBIA 30th of January 2013.
Institut der beim Europäischen Patentamt zugelassenen Vertreter Institute of Professional Representatives before the European Patent Office Institut des.
1 “Introduction to EU Trade Policy” – July 2008 How We Make Trade Policy n Contents n Part I: EU Trade Powers n Part II: The evolving scope of Trade Policy.
Access to the European Court of Justice: is the door unbolted? Access to the European Court of Justice: is the door unbolted? Carol Hatton SolicitorWWF-UK.
Industrial Property the Patent system
Intellectual Property Rights (IPR)
LATEST DEVELOPMENTS IN BIOTECH PATENTS Carine van den Brink 18 April 2012.
Selected Cases on Patents and Biotechnology WIPO-UKRAINE SUMMER SCHOOL ON INTELLECTUAL PROPERTY – JULY 2011.
IP rights and competition law: Friends or foes? Etienne Wéry Attorney at the bars of Paris and Brussels Lecturer at Robert Schuman University (Strasbourg)
INTRODUCTION INTO PRIVATE INTERNATIONAL LAW OF THE EUROPEAN UNION Marko Jovanovic, LL.M. MASTER IN EUROPEAN INTEGRATION Private International Law in the.
Rome I regulation Discussion topics
Gambling, gaming and sports : what about the personality rights and trademarks? Paul Van den Bulck Partner at Ulys Law Firm (Brussels-Paris) Lecturer at.
A narrow pathway between fences Seminar on free movement of same sex families in Europe European Parliament, 3 May 2011 Pál Szirányi – Permanent representation.
Patentability of Software by Paul Van den Bulck Partner ULYS Law Firm
International Treaty in EU PIL
EU: Bilateral Agreements of Member States
EU: Bilateral Agreements of Member States. Formerly concluded international agreements of Member States with third countries Article 351 TFEU The rights.
Ownership and distribution Ethical issues in patenting Pr Samia Hurst Institute for Biomedical Ethics University of Geneva Medical School.
© J. Straus 2002 CASRIP 2002 High Technology Protection Summit Seattle, July 20, 2002 Ethical Issues in Patent Law Biotechnology and Research Ethics -
Ethics of Patents in Stem Cell Research
The European legal framework for patentability and regulation of stem cells : focus on Germany, Spain and France Paul Van den Bulck Partner at Ulys Law.
20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.
Aurora Plomer, BA, MA, LLB, PhD Professor of Law & Bioethics Director of SIBLE University of Sheffield
The patentability of human pluripotent embryonic stem cells and stem cell lines Paul Van den Bulck Partner at Ulys Law Firm (Brussels) Lecturer at the.
Rodolphe Bauer, Frédéric Dedek, Gareth Jenkins, Cristina Margarido
The legal and ethical dilemma of embryonic stem cells: an impediment to translation in medicine? E. Rial-Sebbag, A. Mahalatchimy, A.M. Duguet.
The Case of Myriad Genetics (Vs. an array of National Government Funded European Union Research Institutes) Amir Zaher UC Berkeley, Senior Department of.
Lawyer at the Brussels Bar Lecturer at the University of Strasbourg Assistant at the University of Brussels Data Protection & Electronic Communications.
J.A.Kemp & Co. London Munich Oxford. FICPI ABC MEETING 2007 EPC 2000 Alan M. Senior 30 May 2007.
Circulation of authentic instruments under Regulation 650/2012 speaker – Ivaylo Ivanov – Bulgarian Notary Chamber.
Patenting Stem Cells of Human Origin ATRIP Conference, Tokyo, 2003 In the wake of the Commission’s first report on the 1998 Directive on the legal protection.
Professor Peng  Patent Act (2008) ◦ Promulgated in 1984 ◦ Amended in 1992, 2000, and 2008.
Page 1 IOP Genomics Workshop Patents and Patenting Biotech Inventions Annemieke Breukink, Ph.D. September 8th, 2009.
EUROPEAN COMMISSION - DG Internal Market 1 "Reviewing the Review: The European Commission's Third Review of the Product Liability Directive"
Second expert group meeting on Draft fiche on delegated act on the European code of conduct on partnership (ECCP) Cohesion Policy
Introduction to Patents Anatomy of a Patent & Procedures for Getting a Patent Margaret Hartnett Commercialisation & IP Manager University.
Access to Genetic Resources & Traditional Knowledge The Bellagio compulsory cross-licensing proposal for benefit sharing consistent with more competition.
NCCR International Trade NCCR IP9 WORKSHOP 28 th March “Prior Informed Consent in European Patent Law: Overview and Options” - Michelangelo R.P.
The application of certain restrictions on access to environmental information in accordance with AC Personal Data Ana Barreira Instituto.
Case 428/08 Monsanto v Cefetra e.a THE FUTURE OF BIOTECH PATENT PROTECTION IN EUROPE What every biotech patent practitioner should know John J. Allen.
Bent Egebart - Corsortium agreements The Commission demand it, but do not check it (?) The Community is not a party to these agreements.
Seminar on EC case-law Bedanna Bapuly Brno, 2007 October 15th.
CUTS International Capacity Building Training Programme on Advance IPR, WTO-Related Issues and Patent Writing April 28-May 02, 2008, Jaipur TRIPS – Article.
European Aviation Safety Agency Head of Aircraft Product Certification
Patenting Animal Genetic Inventions The Ethics of Patenting Animal Genetic Inventions - NCCR PhD Workshop Michelangelo Temmerman.
1 Patent Claim Interpretation under Art. 69 EPC – Should prosecution history be used to interpret the patent? presented at Fordham 19th Annual Conference.
Robert J. Hart CPA, EPA, FBCS Proposal for a Directive on the patentability of computer- implemented inventions  Commission proposal - 20 February 2002.
Basic economic freedoms. 1. Free movement of goods The Community shall be based upon a customs union which shall cover all trade in goods and which shall.
PATENTS, INTEGRATED CIRCUITS, AND INDUSTRIAL DESIGNS Presented By: Navdeep World Trade Organization.
The EU and Access to Environmental Information Unit D4 European Commission, Directorate General for the Environment 1.
15-16 May 2007Geertrui Van OverwalleEUPACO One size fits all? How unitary is the present European patent system? Geertrui Van Overwalle Centre for Intellectual.
Draft fiche on delegated act on the European code of conduct on partnership (ECCP) Structured Dialogue Brussels, 19 September
Introduction The Patentability of Human Genes Is patenting human genes moral? Should it be legal? Should there be international intervention?
M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 27 – Environment Bilateral screening:
The Community Trade Mark (CTM) System. The Legal Framework Council Regulation (EC) No 40/94 of 20 December 1993 on the Community trade mark Council Regulation.
Contact: Serving society Stimulating innovation Supporting legislation Joint Research Centre (JRC) 15 July 2013.
Funding and patentability of stem cell research in the European Union - A critical legal review of European legislation Dr. Malene Rowlandson, University.
Ip4inno 1 Content of the module IP for the creative industries Patented computer-implemented inventions Software Biotechnological inventions.
AIPLA Spring Meeting, Houston Texas
The protection of know-how in franchising networks
Dubravka šimonović Ana borovečki
European Union Law Law 326.
PRESENTATION OF MONTENEGRO
SPCs and the unitary patent package
INTRODUCTION INTO PRIVATE INTERNATIONAL LAW OF THE EUROPEAN UNION
The activity of Art. 29. Working Party György Halmos
Legal Foundations of European Union Law II
Comitology and the Treaty of Lisbon
Presentation transcript:

The patentability of biotechnological inventions: The European Commission’s second 16c report Paul Van den Bulck Partner at Ulys Law Firm (Brussels) Lecturer at R. Schuman University Strasbourg (France) Friday, 5th May

Structure I. Introduction II. Content of the second 16c report (A) latest developments occurred since the publication of the first 16c report (B) the scope of patents on sequences or partial sequences of genes which have been isolated from the human body (C) the patentability of embryonic human stem cells and cell lines obtained from them

I. Introduction

 Directive 98/44/EC of 6 July 1998 on the legal protection of biotechnological inventions  Article 16c of the Directive: “The Commission shall send the European Parliament and the Council […] annually as from the date specified in Article 15(1), a report on the development and implications of patent law in the field of biotechnology and genetic engineering.”

 the first 16c report ( dealt with:  the implementation of the Directive in Europe;  the compatibility of the Directive with the relevant international agreements ;  the patentability of inventions relating to plants and animals;  the patentability of inventions relating to elements isolated from the human body;  exclusion from patentability of inventions whose commercial exploitation would be contrary to ordre public or morality.

 the second 16c report of 14 July 2005 ( _doc?smartapi!celexapi!prod!CELEXnumd oc&lg=en&numdoc=52005DC0312&model =guichett) _doc?smartapi!celexapi!prod!CELEXnumd oc&lg=en&numdoc=52005DC0312&model =guichett  involvement of the Group of Experts and the European Group on Ethics

II. The second 16c report

A. latest developments occurred since the publication of the first 16c report  the European Commission draws the state of progress regarding the transposition of the Directive into the national legislation of the EC Member States: 21 Member States have notified the Commission their legal instruments implementing the Directive

 Setting up of a group of Experts to advise the Commission on the preparation of 16c reports.

 The European Commission reports that the adoption of Council Regulation amending Regulation 2100/94 on Community plant variety rights in order to render Article 29 of Regulation 2100/94 and Article 12 of the Directive mutually compatible. These provisions deal with cross-licenses on patent and plant variety rights.

B. the scope of patents on (partial) sequences of genes which have been isolated from the human body  The European Commission addresses the question on whether patents on DNA sequences should be allowed according to:  the classical model of patent claim, i.e. the inventor claims an invention which covers possible future uses of that sequence; or  the “purpose-bound protection” model, i.e. a restriction of the patent so that only the specific use disclosed in the patent application can be claimed?

 Laws implementing Directive 98/44 in France and Germany provide for purpose-bound protection:  France: Art. L , Code de la propriété intellectuelle  Germany: S. 1a (4), Patentgesetz  In the second 16c report, the European Commission does not take position on the validity of transposition of the Directive, by the Member States, according to the choice between classical and limited scope of protection for gene sequences.

C. the patentability of human embryonic stem cells and cell lines obtained from them  General context : patentability of human stem cells and cell lines.  Article 5 (2) of the Directive: “An element isolated from the human body...including the sequence or partial sequence of a gene, may constitute a patentable invention, even if the structure of that element is identical to that of a natural element.”

 Article 5 (2) of the Directive:  allows for the patentability of human stem cells; and  allows for the patentability of human stem cell lines (if the invention is new, involves an inventive step and is susceptible of industrial application)

 As regards to human embryonic stem cells, one has to distinguish:  totipotent stem cells which are capable of developing into a human being  pluripotent stem cells which are not so capable

 Article 5 (1) of the Directive: “The human body, at the various stages of its formation and development, and the simple discovery of one of its elements... cannot constitute patentable inventions.”  totipotent stem cells = unpatentable (since they are capable of developing into a human being)  What about the patentability of pluripotent stem cells? According to the European Commisson: a more complex situation

Article 6 of the Directive: 1.Inventions shall be considered unpatentable where their commercial exploitation would be contrary to ordre public or morality; 2....the following, in particular, shall be considered unpatentable: (...) (c) uses of human embryos for industrial or commercial purposes;...

 Article 6(2)c): does the unpatentability concerns (i) an embryo as a whole or (ii) every invention concerning embryonic stem cells? No consensus within the Group of Experts.  Importance of the interpretation of the concept of “embryo” in the national legislation of the Member States

 the European Commission refrains from giving a further definition or to provide for further harmonization in the area of Article 6(2)c)  the European Commission concludes that “there is no immediate answer to the question of the patentability of embryonic pluripotent stem cells.”

‘EDINBURGH PATENT’- case :  Patent granted in December 1999  patent for ‘animal transgenic stem cells’  EPO Opposition Proceedings (July 2002):  amendment to exclude human embryonic stem cells  adopted broad interpretation of Rule 23(d)(c) (6(2)c of directive)  does this mean that human embryonic stem cells are unpatentable ?  The decision of the Board of Appeal is awaited (end 2006)

TO BE CONTINUED……

Paul Van den Bulck Partner at Ulys Law Firm (Brussels) Lecturer at R. Schuman University Strasbourg (France) & Q uestions A nswers